MedTrace Logo

CGMIS 48-hour Feasibility Study

NCT05562206 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-09-30

No results posted yet for this study

Summary

This is a single center, single arm non-randomized study of 48-hour CGMIS wear duration incorporating two meal-challenge tests to explore the performance of a single insertion combined glucose-sensing insulin delivery cannula.

Conditions

  • Type1diabetes

Interventions

DEVICE

CGMIS (Continuous Glucose Monitoring Infusion Set)

An integrated combination CGM/insulin infusion system

Sponsors & Collaborators

  • Pacific Diabetes Technologies

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-30
Primary Completion
2022-10-31
Completion
2022-11-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05562206 on ClinicalTrials.gov